Plexus Corp. (PLXS)
Valor JustoFundamental
62
Preço
$260.95
Capitalização de Mercado
$6.95B
Parte 1 · Quanto vale a empresa
Visão Geral
Plexus Corp. is a US contract manufacturer and product-realisation partner: it does not sell products under its own brand, it designs, engineers, manufactures and services complex electronic products for other companies. It deliberately concentrates on highly regulated, low-volume/high-mix products — surgical and diagnostic instruments, factory automation and semiconductor capital equipment, avionics and defence electronics — rather than on consumer electronics built by the million. In fiscal 2025 (year ended 27 September 2025) it reported net sales of $4.033 billion, served roughly 190 customers and employed over 20,000 people across 26 facilities, organised into three geographic reportable segments: the Americas (AMER), Asia-Pacific (APAC) and Europe, Middle East and Africa (EMEA).
Como gera receita
Revenue comes from making and shipping products for customers. Most work is 'turnkey': Plexus buys the components itself, builds the product and bills a price that covers materials plus its own value added, so the bill of materials flows through the income statement and keeps reported margins structurally thin. A smaller share is 'consignment', where the customer supplies the parts and Plexus charges only for labour and services. The company also earns fees for design, engineering and sustaining services (repair, refurbishment, spare parts), which usually come before and after the manufacturing phase of a programme. The 10-K states that Plexus generally does not obtain firm, long-term purchase commitments: customers issue forecasts and short-horizon orders, Plexus finances the material purchase in advance, and many contracts allow prices to be renegotiated periodically — often quarterly — when component costs move.
Receita por segmento
Factory automation, semiconductor capital equipment, test and measurement instruments, energy and communications hardware, built for industrial OEMs.
Surgical, diagnostic, imaging, drug-delivery and laboratory instruments made for medical device and life-science companies in FDA-registered facilities.
Avionics, cabin and mission systems and defence electronics supplied to aerospace and defence primes and their suppliers.
Vantagem competitiva
Custos de mudança · EstreitaContract manufacturing is a competitive, low-margin business and Plexus openly says it faces many rivals, some far larger. What softens that is the kind of work it takes on: a surgical instrument or an avionics box is qualified with the regulator at a named site, under FDA, aerospace and defence quality regimes, and often after Plexus has helped design it. Moving such a programme to another supplier means requalification, revalidation and schedule risk, so programmes tend to stay put for the life of the product. The advantage protects existing programmes rather than pricing power on new ones, which is why it is better read as narrow than wide.
O que impulsiona a procura
Moderadamente cíclicoDemand is driven by customers' new product launches and by their capital and equipment spending, so it arrives in programme ramps rather than as a steady flow. The mix splits the cycle: healthcare and life-science instruments (40% of fiscal 2025 sales) hold up reasonably well through downturns, while industrial work (43%) — factory automation, semiconductor capital equipment, test and measurement — swings with industrial capex and the semiconductor cycle, and aerospace/defence (17%) follows long, slow-moving programme and budget schedules. Because Plexus buys materials ahead of forecasts, a slowdown shows up first as inventory and unabsorbed capacity, and only then in sales.
Principais riscos
- No firm long-term purchase commitments — Plexus discloses that it generally works from customer forecasts rather than binding long-term orders. Customers can cancel, delay or reduce volumes, and the company may be left with inventory and capacity built against a forecast that did not materialise.
- Concentration in a limited number of customers and sectors — A large slice of revenue comes from a small group of customers and from three market sectors. The loss of a major customer, or a downturn confined to one sector, would hit results even though no single customer reached 10% of sales in fiscal 2025.
- Component availability, supplier delays and price volatility — Because Plexus buys the materials on turnkey programmes, shortages, allocation or sudden price increases can delay shipments and squeeze margins, especially where contract pricing can only be adjusted at set intervals.
- Inventory build and obsolescence — The company carries significant inventory purchased ahead of customer demand. If a programme is cancelled, redesigned or ramps more slowly than forecast, that inventory can become excess or obsolete and require write-downs.
- Competitive and pricing pressure — Plexus competes with other electronics manufacturing services providers and with customers' own in-house operations. Competitors with greater scale or lower cost structures can force price concessions in a business that already runs on thin operating margins.
- Regulatory burden in medical, aerospace and defence work — Facilities serving these sectors are subject to quality-system, export-control and government-contracting rules. Failing an audit, losing a certification or breaching export rules could interrupt production and expose the company to penalties.
- Multinational operations and geopolitical exposure — Manufacturing is spread across the Americas, Asia-Pacific and EMEA, which exposes Plexus to tariffs and trade restrictions, currency movements, labour cost inflation and political instability in the countries where it builds.
- Dependence on customers' technology and product cycles — Plexus' revenue follows products it does not own. If a customer's product loses its market, is superseded by new technology or never reaches volume, the associated programme revenue disappears with it.
Concentração de clientes
Os principais clientes representam 49.1% da receita
The 10-K states that the ten largest customers accounted for 49.1% of net sales in fiscal 2025, up from 47.8% in fiscal 2024, and that no single customer represented more than 10% of sales in either year. So roughly half the business rests on ten relationships out of about 190 customers — concentrated, but without one name whose departure would dominate the rest.
Os argumentos a favor
Buyers argue that Plexus has chosen the defensible corner of contract manufacturing: regulated, complex, low-volume products that are expensive to move once qualified, in sectors where the customer cares more about quality systems than about the last cent of price. They point to fiscal 2025 revenue of $4.033 billion, GAAP operating margin of 5.0% and non-GAAP diluted EPS of $7.43, to 28 manufacturing programme wins in the year, and to $154 million of free cash flow as evidence that the model converts work into cash. They add that the healthcare and life-science base gives a stable floor while the industrial and aerospace/defence programmes won in recent years are still ramping, and that management has framed a path back toward faster revenue growth.
Os argumentos contra
Sellers fear that the economics stay thin whatever the mix: a 5.0% GAAP operating margin leaves little cushion, and because Plexus buys the components it carries the working capital and the obsolescence risk of products other people design. Without firm long-term commitments, a customer can cut or cancel a programme and leave inventory and capacity behind; pricing on new programmes is contested by larger rivals and by customers' own in-house plants. They also point to the concentration — half of sales in ten relationships, 43% of sales tied to industrial capex and the semiconductor cycle — and to a global footprint exposed to tariffs, trade restrictions and currency swings, where a single lost certification or failed regulatory audit at one qualified site could stop a programme outright.
Generated on 19 de setembro de 2026 with claude-haiku-4-5 — shared with all users
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balanço & Liquidez
Receita
$4.03B
Últimos 12 meses (até 04/07/2026)
Resultado Líquido
$185M
Últimos 12 meses (até 04/07/2026)
Fluxo de Caixa Livre
$154M
Capital Próprio Total
$1.45B
Passivo Total
$1.68B
Rácio de Liquidez
1.49
Cobertura de Juros
18.00
Dívida/EBITDA
1.10
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$233.25
Preço Atual
$260.95
Margem de Segurança
-11.9%
Intervalo de Valor Justo
$158.96 - $307.53
Dispersão entre os métodos de avaliação utilizados, não um intervalo de confiança calibrado estatisticamente.
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
38.49
ROE
11.9%
Rácio P/B
4.55
P/FCF
112.41
Margem Bruta
11.4%
ROIC
10.8%
Radar de Rentabilidade
Criação de Valor (Vantagem Competitiva)
ROIC
10.8%
WACC
9.4%
ROIC − WACC
+1.4 pp
O ROIC supera o custo do capital — a empresa está a criar valor para os acionistas.
Critérios de Análise Fundamental
Aprovado (19)
- EPS shows upward trend
- EPS CAGR 7.20%
- Price CAGR 17.19%
- ROIC 10.8%
- Debt/Equity ratio
- Operating Margin 5.7%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 12.5%
- Analyst Consensus 77% Buy
- Earnings Surprise avg 6.4%
- Earnings Quality (OCF/NI) 0.92
- Share Dilution -1.0%
- Net Margin Trend 4.6% vs 4.1%
- Piotroski F-Score 9/9
Reprovado (8)
- Gross Margin 11.4%
- P/FCF 112.41
- P/B Ratio 4.55
- CapEx intensity
- Price below Graham Number
- DCF valuation (Overvalued)
- Revenue Growth 5Y 3.5%
- PEG Ratio 3.91
Indisponível (1)
- Dividend Payout NaN%
Piotroski F-Score
Saúde financeira sólida
Qualidade dos Resultados
Moderada: alguma diferença entre lucros e caixa
Diluição de Ações
A recomprar ações. Favorável ao acionista
Participações institucionais
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Mr. Todd P. Kelsey | President, CEO & Director | 60 |
| Mr. Oliver K. Mihm | Executive VP & COO | 53 |
| Mr. Angelo M. Ninivaggi J.D. | Executive VP, Chief Legal & Public Affairs Officer and Secretary | 58 |
| Mr. Victor Tan | Regional President of APAC | 61 |
| Mr. David Abuhl | CFO & Senior VP | - |
| Mr. Kyle McMillan | Chief Information & Technology Officer | - |
| Mr. Shawn Matthew Harrison | Vice President of Investor Relations | - |
| Ms. Lori Ney | Chief Human Resources Officer | - |
| Mr. Michael J. Running | Regional President of AMER | 49 |
| Mr. Scott Theune | Chief Quality Officer | 60 |
Risco de Auditoria
2
Risco do Conselho
4
Risco de Remuneração
1
Risco dos Direitos dos Acionistas
2
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Documentos
- Ver documento
Relatório anual (10-K)
Uma visão anual do negócio, dos resultados financeiros e dos riscos da empresa.
Arquivado em 2025-11-14
- Ver documento
Relatório trimestral (10-Q)
Uma atualização sobre o desempenho financeiro dos últimos três meses.
Arquivado em 2026-08-06
- Ver documento
Relatório de fato relevante (8-K)
Um aviso sobre um fato relevante, como uma mudança na liderança ou um grande anúncio.
Arquivado em 2026-08-24
via SEC EDGAR
Histórico de Resultados
via SEC EDGAR
Latest News
Recent headlines for PLXS, sourced from Markets Gazette.
- 4/20/2026POSITIVEThis Plexus Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday
Wall Street analysts have initiated a bullish stance on Plxus Inc., upgrading the stock and raising its price target. This positive analyst sentiment suggests a favorable outlook for the company's future performance, potentially driven by new product developments, market share gains, or improved financial projections. Investors often view such upgrades as indicators of potential stock price appreciation, prompting a closer look at Plxus's fundamentals and competitive positioning.
via Markets Gazette